When to Stop Mounjaro: What the Guidance Actually Says

You've hit six months and the scales haven't moved much

Picture this: you started Mounjaro with real commitment, you've worked through the early nausea, you've titrated slowly, and now six months have passed. The weight loss has been modest. It's a frustrating place to be, and it's one our prescribers hear about regularly.

NICE's appraisal of tirzepatide sets a practical checkpoint here. If you have not achieved at least 5% weight loss after six months at the highest dose you can tolerate, the guidance recommends reviewing whether continuing treatment makes clinical sense. That review is not automatic — it involves your prescriber looking at your full picture, including how you've tolerated the medicine, whether anything else might explain a slower response, and what alternatives exist.

This is also the point where it's worth understanding what the evidence shows more broadly. In SURMOUNT-1, thousands of adults on tirzepatide achieved around 20–21% average weight reduction over 72 weeks at the highest dose, according to the NICE appraisal of tirzepatide (TA1026). Not everyone responds equally, and some people reach the six-month mark without meaningful progress despite doing everything right. The six-month rule exists precisely to avoid indefinite treatment where the benefit has not materialised.

If you're at this point and unsure what to do, it's a prescriber conversation, not one to navigate alone. You can explore your options through a free consultation at nume.

A medical reason makes continuing unsafe

Some situations make stopping Mounjaro the immediate priority, regardless of how well your weight loss has been going.

The clearest is pregnancy. Mounjaro is not recommended during pregnancy, breastfeeding, or in the period before trying to conceive. Women of childbearing age should use effective contraception throughout treatment; for those using oral contraceptives specifically, additional non-oral contraception is needed during the first four weeks of treatment and for four weeks after any dose increase, because tirzepatide can reduce how well the pill is absorbed. Your prescriber will advise on the practical steps and timing before you stop, including the wash-out period the MHRA recommends before trying to conceive.

Certain diagnosed conditions also mean Mounjaro may no longer be suitable: a history of medullary thyroid carcinoma or MEN2, active pancreatitis, or specific gastrointestinal conditions. If a new diagnosis emerges during treatment, contact your prescriber promptly. You can find the full contraindication detail in the Mounjaro SmPC on the eMC.

There is also a common misconception worth addressing gently: many people assume that a side effect in the first few weeks means the medicine will never suit them and they should stop. In most cases, gastrointestinal side effects (nausea, loose stools, indigestion) are most pronounced during the early dose stages and ease over days to a couple of weeks. That doesn't mean you push through anything severe; it means a rough first fortnight is not the same as a red flag. Persistent, severe abdominal pain that spreads toward the back is different, stop and seek medical help straight away, as this can be a sign of pancreatitis, which the MHRA flagged formally in its January 2026 Drug Safety Update for GLP-1 medicines.

When you stop mounjaro: what happens next

Stopping is a decision with consequences, and it is worth going in with clear expectations rather than discovering them afterwards.

Tirzepatide works, in part, by suppressing appetite through GIP and GLP-1 receptor pathways. When the medicine leaves your system, that suppression lifts. Most people find hunger returns, often within a few weeks. Weight can return too, and sometimes fairly quickly. This is biology, not backsliding. Understanding what happens to weight loss when tirzepatide is stopped helps set realistic expectations.

The practical questions matter as well: how do you stop (gradually or immediately), do you need to do anything in the days after the last injection, and what monitoring makes sense? There is no evidence-based requirement to taper Mounjaro, unlike some other medicines, the guidance does not mandate a gradual reduction schedule. But a planned stop, with your prescriber aware and a plan in place, is different from simply not reordering. Our guide to when you should stop Mounjaro can help you think through whether the timing is right for your situation, and for more on the practicalities, our page on how to stop Mounjaro covers the step-by-step detail.

If you stopped because you reached your weight goal, the conversation shifts to maintenance. Some people, under clinical supervision, continue at a lower dose or with extended dosing intervals. Others stop entirely and manage weight through diet and activity, sometimes returning to treatment if weight regain becomes significant. That plan is individual and should be made with a prescriber who knows your case. Our clinical team can review the options with you.

When stopping might be the wrong decision

Not every reason to stop is a good one, and it's honest to say so.

Cost pressure is real. Private treatment is not cheap, and the financial strain of monthly prescriptions is something people weigh carefully. There are pages on what weight-loss treatment involves and what Mounjaro treatment looks like in practice that might help you think through the value question. But stopping a clinically effective medicine purely because of cost, without an alternative plan, can leave you in a harder position six months on.

Plateaus are another common trigger for stopping, and often a premature one. A period of slower or stalled weight loss during treatment is normal. It does not necessarily mean the medicine has stopped working; it may mean your body has adjusted or that lifestyle factors have shifted. If you are weighing up the signals carefully, our page covering when to stop tirzepatide sets out the clinical indicators worth considering before making that call. A clinical review is more useful than a unilateral stop in this scenario.

If you are uncertain whether to continue, the right first step is a review with your prescriber. You can also read more about the broader clinical profile of tirzepatide to understand the longer-term evidence. And if you're thinking about a different approach entirely, a look at our FAQs might help frame the next conversation.